Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine

To combat emerging infectious diseases like Zika virus (ZIKV), synthetic messenger RNAs (mRNAs) encoding viral antigens are very attractive as they allow a rapid, generic, and flexible production of vaccines. In this work, we engineered a self-replicating mRNA (sr-mRNA) vaccine encoding the pre-memb...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2019-08, Vol.7 (3), p.96
Main Authors: Zhong, Zifu, Portela Catani, João Paulo, Mc Cafferty, Séan, Couck, Liesbeth, Van Den Broeck, Wim, Gorlé, Nina, Vandenbroucke, Roosmarijn E, Devriendt, Bert, Ulbert, Sebastian, Cnops, Lieselotte, Michels, Johan, Ariën, Kevin K, Sanders, Niek N
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Clinical trials
Electroporation
Encephalitis
Genomes
Glycoproteins
IFNAR1 knockout mice
Immune response (cell-mediated)
Immune response (humoral)
Immunogenicity
Infectious diseases
Interferon
Molecular biology
mRNA
mRNA vaccines
Plasmids
Proteins
Replication
Robustness
self-replicating mRNA
Seroconversion
type I interferon response
Vaccines
Vector-borne diseases
Vectors (Biology)
Viruses
Zika virus
Zika virus vaccine
β-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c553t-5368ba80d27fb84f8e6e8d34e6c00b1fa16e701036df91522abd8dc01fa4f2f53
cites cdi_FETCH-LOGICAL-c553t-5368ba80d27fb84f8e6e8d34e6c00b1fa16e701036df91522abd8dc01fa4f2f53
container_end_page
container_issue 3
container_start_page 96
container_title Vaccines (Basel)
container_volume 7
creator Zhong, Zifu
Portela Catani, João Paulo
Mc Cafferty, Séan
Couck, Liesbeth
Van Den Broeck, Wim
Gorlé, Nina
Vandenbroucke, Roosmarijn E
Devriendt, Bert
Ulbert, Sebastian
Cnops, Lieselotte
Michels, Johan
Ariën, Kevin K
Sanders, Niek N
description To combat emerging infectious diseases like Zika virus (ZIKV), synthetic messenger RNAs (mRNAs) encoding viral antigens are very attractive as they allow a rapid, generic, and flexible production of vaccines. In this work, we engineered a self-replicating mRNA (sr-mRNA) vaccine encoding the pre-membrane and envelope (prM-E) glycoproteins of ZIKV. Intradermal electroporation of as few as 1 µg of this mRNA-based ZIKV vaccine induced potent humoral and cellular immune responses in BALB/c and especially IFNAR1 C57BL/6 mice, resulting in a complete protection of the latter mice against ZIKV infection. In wild-type C57BL/6 mice, the vaccine resulted in very low seroconversion rates and antibody titers. The potency of the vaccine was inversely related to the dose of mRNA used in wild-type BALB/c or C57BL/6 mice, as robust type I interferon (IFN) response was determined in a reporter mice model (IFN-β ). We further investigated the inability of the sr-prM-E-mRNA ZIKV vaccine to raise antibodies in wild-type C57BL/6 mice and found indications that type I IFNs elicited by this naked sr-mRNA vaccine might directly impede the induction of a robust humoral response. Therefore, we assume that the efficacy of sr-mRNA vaccines after intradermal electroporation might be increased by strategies that temper their inherent innate immunogenicity.
doi_str_mv 10.3390/vaccines7030096
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1b5618da8d044b719326c4221814cff7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1b5618da8d044b719326c4221814cff7</doaj_id><sourcerecordid>2281100974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c553t-5368ba80d27fb84f8e6e8d34e6c00b1fa16e701036df91522abd8dc01fa4f2f53</originalsourceid><addsrcrecordid>eNpdks1rFDEYxoMottSevUnAi5ex-U7mItRS7UKpUrWIl5jJx5rtTLImM4X97zvr1tI2l4T3efLjSd4XgNcYvae0RUc3xtqYfJWIItSKZ2CfICka2tKfzx-c98BhrSs0rxZTJeRLsEcx40hKvg9-L4ZhSnnpU7Rx3ECTHPxa8ujtGHOCpyFEa-wG5gANvDDX3sFvvg_NpV_3szLGtITD5cVx89HUWfsVrw28imWq8GqX7hV4EUxf_eHdfgB-fDr9fnLWnH_5vDg5Pm8s53RsOBWqMwo5IkOnWFBeeOUo88Ii1OFgsPASYUSFCy3mhJjOKWfRrLBAAqcHYLHjumxWel3iYMpGZxP1v0IuS23KGG3vNe64wMoZ5RBjncQtJcIyQrDCzIYgZ9aHHWs9dYN31qexmP4R9LGS4h-9zDdaSNVyug3z7g5Q8t_J11EPsVrf9yb5PFVNiMJ47odks_XtE-sqTyXNX6UJ54hIgtg20dHOZUuutfhwHwYjvR0G_WQY5htvHr7h3v-_9fQW63OxBA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2550272047</pqid></control><display><type>article</type><title>Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine</title><source>PubMed Central (Open Access)</source><source>Publicly Available Content Database</source><creator>Zhong, Zifu ; Portela Catani, João Paulo ; Mc Cafferty, Séan ; Couck, Liesbeth ; Van Den Broeck, Wim ; Gorlé, Nina ; Vandenbroucke, Roosmarijn E ; Devriendt, Bert ; Ulbert, Sebastian ; Cnops, Lieselotte ; Michels, Johan ; Ariën, Kevin K ; Sanders, Niek N</creator><creatorcontrib>Zhong, Zifu ; Portela Catani, João Paulo ; Mc Cafferty, Séan ; Couck, Liesbeth ; Van Den Broeck, Wim ; Gorlé, Nina ; Vandenbroucke, Roosmarijn E ; Devriendt, Bert ; Ulbert, Sebastian ; Cnops, Lieselotte ; Michels, Johan ; Ariën, Kevin K ; Sanders, Niek N</creatorcontrib><description>To combat emerging infectious diseases like Zika virus (ZIKV), synthetic messenger RNAs (mRNAs) encoding viral antigens are very attractive as they allow a rapid, generic, and flexible production of vaccines. In this work, we engineered a self-replicating mRNA (sr-mRNA) vaccine encoding the pre-membrane and envelope (prM-E) glycoproteins of ZIKV. Intradermal electroporation of as few as 1 µg of this mRNA-based ZIKV vaccine induced potent humoral and cellular immune responses in BALB/c and especially IFNAR1 C57BL/6 mice, resulting in a complete protection of the latter mice against ZIKV infection. In wild-type C57BL/6 mice, the vaccine resulted in very low seroconversion rates and antibody titers. The potency of the vaccine was inversely related to the dose of mRNA used in wild-type BALB/c or C57BL/6 mice, as robust type I interferon (IFN) response was determined in a reporter mice model (IFN-β ). We further investigated the inability of the sr-prM-E-mRNA ZIKV vaccine to raise antibodies in wild-type C57BL/6 mice and found indications that type I IFNs elicited by this naked sr-mRNA vaccine might directly impede the induction of a robust humoral response. Therefore, we assume that the efficacy of sr-mRNA vaccines after intradermal electroporation might be increased by strategies that temper their inherent innate immunogenicity.</description><identifier>ISSN: 2076-393X</identifier><identifier>EISSN: 2076-393X</identifier><identifier>DOI: 10.3390/vaccines7030096</identifier><identifier>PMID: 31450775</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Antigens ; Clinical trials ; Electroporation ; Encephalitis ; Genomes ; Glycoproteins ; IFNAR1 knockout mice ; Immune response (cell-mediated) ; Immune response (humoral) ; Immunogenicity ; Infectious diseases ; Interferon ; Molecular biology ; mRNA ; mRNA vaccines ; Plasmids ; Proteins ; Replication ; Robustness ; self-replicating mRNA ; Seroconversion ; type I interferon response ; Vaccines ; Vector-borne diseases ; Vectors (Biology) ; Viruses ; Zika virus ; Zika virus vaccine ; β-Interferon</subject><ispartof>Vaccines (Basel), 2019-08, Vol.7 (3), p.96</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c553t-5368ba80d27fb84f8e6e8d34e6c00b1fa16e701036df91522abd8dc01fa4f2f53</citedby><cites>FETCH-LOGICAL-c553t-5368ba80d27fb84f8e6e8d34e6c00b1fa16e701036df91522abd8dc01fa4f2f53</cites><orcidid>0000-0001-6683-5658 ; 0000-0003-4585-0343 ; 0000-0002-8327-620X ; 0000-0002-3222-8769 ; 0000-0002-1340-4165</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2550272047/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2550272047?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31450775$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhong, Zifu</creatorcontrib><creatorcontrib>Portela Catani, João Paulo</creatorcontrib><creatorcontrib>Mc Cafferty, Séan</creatorcontrib><creatorcontrib>Couck, Liesbeth</creatorcontrib><creatorcontrib>Van Den Broeck, Wim</creatorcontrib><creatorcontrib>Gorlé, Nina</creatorcontrib><creatorcontrib>Vandenbroucke, Roosmarijn E</creatorcontrib><creatorcontrib>Devriendt, Bert</creatorcontrib><creatorcontrib>Ulbert, Sebastian</creatorcontrib><creatorcontrib>Cnops, Lieselotte</creatorcontrib><creatorcontrib>Michels, Johan</creatorcontrib><creatorcontrib>Ariën, Kevin K</creatorcontrib><creatorcontrib>Sanders, Niek N</creatorcontrib><title>Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine</title><title>Vaccines (Basel)</title><addtitle>Vaccines (Basel)</addtitle><description>To combat emerging infectious diseases like Zika virus (ZIKV), synthetic messenger RNAs (mRNAs) encoding viral antigens are very attractive as they allow a rapid, generic, and flexible production of vaccines. In this work, we engineered a self-replicating mRNA (sr-mRNA) vaccine encoding the pre-membrane and envelope (prM-E) glycoproteins of ZIKV. Intradermal electroporation of as few as 1 µg of this mRNA-based ZIKV vaccine induced potent humoral and cellular immune responses in BALB/c and especially IFNAR1 C57BL/6 mice, resulting in a complete protection of the latter mice against ZIKV infection. In wild-type C57BL/6 mice, the vaccine resulted in very low seroconversion rates and antibody titers. The potency of the vaccine was inversely related to the dose of mRNA used in wild-type BALB/c or C57BL/6 mice, as robust type I interferon (IFN) response was determined in a reporter mice model (IFN-β ). We further investigated the inability of the sr-prM-E-mRNA ZIKV vaccine to raise antibodies in wild-type C57BL/6 mice and found indications that type I IFNs elicited by this naked sr-mRNA vaccine might directly impede the induction of a robust humoral response. Therefore, we assume that the efficacy of sr-mRNA vaccines after intradermal electroporation might be increased by strategies that temper their inherent innate immunogenicity.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Clinical trials</subject><subject>Electroporation</subject><subject>Encephalitis</subject><subject>Genomes</subject><subject>Glycoproteins</subject><subject>IFNAR1 knockout mice</subject><subject>Immune response (cell-mediated)</subject><subject>Immune response (humoral)</subject><subject>Immunogenicity</subject><subject>Infectious diseases</subject><subject>Interferon</subject><subject>Molecular biology</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Plasmids</subject><subject>Proteins</subject><subject>Replication</subject><subject>Robustness</subject><subject>self-replicating mRNA</subject><subject>Seroconversion</subject><subject>type I interferon response</subject><subject>Vaccines</subject><subject>Vector-borne diseases</subject><subject>Vectors (Biology)</subject><subject>Viruses</subject><subject>Zika virus</subject><subject>Zika virus vaccine</subject><subject>β-Interferon</subject><issn>2076-393X</issn><issn>2076-393X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdks1rFDEYxoMottSevUnAi5ex-U7mItRS7UKpUrWIl5jJx5rtTLImM4X97zvr1tI2l4T3efLjSd4XgNcYvae0RUc3xtqYfJWIItSKZ2CfICka2tKfzx-c98BhrSs0rxZTJeRLsEcx40hKvg9-L4ZhSnnpU7Rx3ECTHPxa8ujtGHOCpyFEa-wG5gANvDDX3sFvvg_NpV_3szLGtITD5cVx89HUWfsVrw28imWq8GqX7hV4EUxf_eHdfgB-fDr9fnLWnH_5vDg5Pm8s53RsOBWqMwo5IkOnWFBeeOUo88Ii1OFgsPASYUSFCy3mhJjOKWfRrLBAAqcHYLHjumxWel3iYMpGZxP1v0IuS23KGG3vNe64wMoZ5RBjncQtJcIyQrDCzIYgZ9aHHWs9dYN31qexmP4R9LGS4h-9zDdaSNVyug3z7g5Q8t_J11EPsVrf9yb5PFVNiMJ47odks_XtE-sqTyXNX6UJ54hIgtg20dHOZUuutfhwHwYjvR0G_WQY5htvHr7h3v-_9fQW63OxBA</recordid><startdate>20190823</startdate><enddate>20190823</enddate><creator>Zhong, Zifu</creator><creator>Portela Catani, João Paulo</creator><creator>Mc Cafferty, Séan</creator><creator>Couck, Liesbeth</creator><creator>Van Den Broeck, Wim</creator><creator>Gorlé, Nina</creator><creator>Vandenbroucke, Roosmarijn E</creator><creator>Devriendt, Bert</creator><creator>Ulbert, Sebastian</creator><creator>Cnops, Lieselotte</creator><creator>Michels, Johan</creator><creator>Ariën, Kevin K</creator><creator>Sanders, Niek N</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6683-5658</orcidid><orcidid>https://orcid.org/0000-0003-4585-0343</orcidid><orcidid>https://orcid.org/0000-0002-8327-620X</orcidid><orcidid>https://orcid.org/0000-0002-3222-8769</orcidid><orcidid>https://orcid.org/0000-0002-1340-4165</orcidid></search><sort><creationdate>20190823</creationdate><title>Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine</title><author>Zhong, Zifu ; Portela Catani, João Paulo ; Mc Cafferty, Séan ; Couck, Liesbeth ; Van Den Broeck, Wim ; Gorlé, Nina ; Vandenbroucke, Roosmarijn E ; Devriendt, Bert ; Ulbert, Sebastian ; Cnops, Lieselotte ; Michels, Johan ; Ariën, Kevin K ; Sanders, Niek N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c553t-5368ba80d27fb84f8e6e8d34e6c00b1fa16e701036df91522abd8dc01fa4f2f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Clinical trials</topic><topic>Electroporation</topic><topic>Encephalitis</topic><topic>Genomes</topic><topic>Glycoproteins</topic><topic>IFNAR1 knockout mice</topic><topic>Immune response (cell-mediated)</topic><topic>Immune response (humoral)</topic><topic>Immunogenicity</topic><topic>Infectious diseases</topic><topic>Interferon</topic><topic>Molecular biology</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Plasmids</topic><topic>Proteins</topic><topic>Replication</topic><topic>Robustness</topic><topic>self-replicating mRNA</topic><topic>Seroconversion</topic><topic>type I interferon response</topic><topic>Vaccines</topic><topic>Vector-borne diseases</topic><topic>Vectors (Biology)</topic><topic>Viruses</topic><topic>Zika virus</topic><topic>Zika virus vaccine</topic><topic>β-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhong, Zifu</creatorcontrib><creatorcontrib>Portela Catani, João Paulo</creatorcontrib><creatorcontrib>Mc Cafferty, Séan</creatorcontrib><creatorcontrib>Couck, Liesbeth</creatorcontrib><creatorcontrib>Van Den Broeck, Wim</creatorcontrib><creatorcontrib>Gorlé, Nina</creatorcontrib><creatorcontrib>Vandenbroucke, Roosmarijn E</creatorcontrib><creatorcontrib>Devriendt, Bert</creatorcontrib><creatorcontrib>Ulbert, Sebastian</creatorcontrib><creatorcontrib>Cnops, Lieselotte</creatorcontrib><creatorcontrib>Michels, Johan</creatorcontrib><creatorcontrib>Ariën, Kevin K</creatorcontrib><creatorcontrib>Sanders, Niek N</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>ProQuest research library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Vaccines (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhong, Zifu</au><au>Portela Catani, João Paulo</au><au>Mc Cafferty, Séan</au><au>Couck, Liesbeth</au><au>Van Den Broeck, Wim</au><au>Gorlé, Nina</au><au>Vandenbroucke, Roosmarijn E</au><au>Devriendt, Bert</au><au>Ulbert, Sebastian</au><au>Cnops, Lieselotte</au><au>Michels, Johan</au><au>Ariën, Kevin K</au><au>Sanders, Niek N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine</atitle><jtitle>Vaccines (Basel)</jtitle><addtitle>Vaccines (Basel)</addtitle><date>2019-08-23</date><risdate>2019</risdate><volume>7</volume><issue>3</issue><spage>96</spage><pages>96-</pages><issn>2076-393X</issn><eissn>2076-393X</eissn><abstract>To combat emerging infectious diseases like Zika virus (ZIKV), synthetic messenger RNAs (mRNAs) encoding viral antigens are very attractive as they allow a rapid, generic, and flexible production of vaccines. In this work, we engineered a self-replicating mRNA (sr-mRNA) vaccine encoding the pre-membrane and envelope (prM-E) glycoproteins of ZIKV. Intradermal electroporation of as few as 1 µg of this mRNA-based ZIKV vaccine induced potent humoral and cellular immune responses in BALB/c and especially IFNAR1 C57BL/6 mice, resulting in a complete protection of the latter mice against ZIKV infection. In wild-type C57BL/6 mice, the vaccine resulted in very low seroconversion rates and antibody titers. The potency of the vaccine was inversely related to the dose of mRNA used in wild-type BALB/c or C57BL/6 mice, as robust type I interferon (IFN) response was determined in a reporter mice model (IFN-β ). We further investigated the inability of the sr-prM-E-mRNA ZIKV vaccine to raise antibodies in wild-type C57BL/6 mice and found indications that type I IFNs elicited by this naked sr-mRNA vaccine might directly impede the induction of a robust humoral response. Therefore, we assume that the efficacy of sr-mRNA vaccines after intradermal electroporation might be increased by strategies that temper their inherent innate immunogenicity.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31450775</pmid><doi>10.3390/vaccines7030096</doi><orcidid>https://orcid.org/0000-0001-6683-5658</orcidid><orcidid>https://orcid.org/0000-0003-4585-0343</orcidid><orcidid>https://orcid.org/0000-0002-8327-620X</orcidid><orcidid>https://orcid.org/0000-0002-3222-8769</orcidid><orcidid>https://orcid.org/0000-0002-1340-4165</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2076-393X
ispartof Vaccines (Basel), 2019-08, Vol.7 (3), p.96
issn 2076-393X
2076-393X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_1b5618da8d044b719326c4221814cff7
source PubMed Central (Open Access); Publicly Available Content Database
subjects Antibodies
Antigens
Clinical trials
Electroporation
Encephalitis
Genomes
Glycoproteins
IFNAR1 knockout mice
Immune response (cell-mediated)
Immune response (humoral)
Immunogenicity
Infectious diseases
Interferon
Molecular biology
mRNA
mRNA vaccines
Plasmids
Proteins
Replication
Robustness
self-replicating mRNA
Seroconversion
type I interferon response
Vaccines
Vector-borne diseases
Vectors (Biology)
Viruses
Zika virus
Zika virus vaccine
β-Interferon
title Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A50%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20and%20Protection%20Efficacy%20of%20a%20Naked%20Self-Replicating%20mRNA-Based%20Zika%20Virus%20Vaccine&rft.jtitle=Vaccines%20(Basel)&rft.au=Zhong,%20Zifu&rft.date=2019-08-23&rft.volume=7&rft.issue=3&rft.spage=96&rft.pages=96-&rft.issn=2076-393X&rft.eissn=2076-393X&rft_id=info:doi/10.3390/vaccines7030096&rft_dat=%3Cproquest_doaj_%3E2281100974%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c553t-5368ba80d27fb84f8e6e8d34e6c00b1fa16e701036df91522abd8dc01fa4f2f53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2550272047&rft_id=info:pmid/31450775&rfr_iscdi=true